Back to All Studies

Trametinib is an FDA-approved drug for people with certain cancers. The drug attacks specific types of cancer cells with less harm to normal cells and blocks mechanisms that cancer cells use to keep replicating continuously. Researchers will conduct a small, preliminary clinical trial to see if dogs with aggressive cancers also can benefit from treatment with trametinib. The team will determine an optimal dose for dogs that is both safe and effective in turning off tumor growth signals. The team also will test a simple blood test that can be used to quickly if effective drug levels are present in the enrolled patients. If successful, findings will help inform studies in larger population of dogs with aggressive cancers.

Study ID
D20CA-810
Study Status
Active
Start Date
10/01/2019
Grant amount awarded
$10,800
Grant recipient
University of Wisconsin-Madison
Study country
United States
Investigator
David M. Vail, DVM
Study category
Cancer